In this study, we identified a new gene fusion, FOXP2-CPED1, in 2 of 100 indolent prostate tumors by performing RNA sequencing and whole-genome sequencing analyzes (Figure 1A and B, Figure 1—figure supplement 1A–E, and Supplementary file 1a and b). This evidence concerns the gene FOXP2 and prostate neoplasm.